Literature DB >> 28687109

Prophylactic Therapy for Hereditary Angioedema.

Hilary Longhurst1, Emily Zinser2.   

Abstract

Long-term prophylaxis is needed in many patients with hereditary angioedema and poses many challenges. Attenuated androgens are effective in many but are limited by side effect profiles. There is less evidence for efficacy of tranexamic acid and progestagens; however, the small side effect profile makes tranexamic acid an option for prophylaxis in children and progestagens an option for women. C1 inhibitor is beneficial, but at present requires intravenous delivery and may need dose titration for maximum efficacy. Short-term prophylaxis should be considered for all procedures. New therapies are promising in overcoming many problems encountered with current options for long-term prophylaxis.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Androgens; C1 inhibitor; Hereditary angioedema; Progestagens; Prophylaxis; Tranexamic acid

Mesh:

Substances:

Year:  2017        PMID: 28687109     DOI: 10.1016/j.iac.2017.04.003

Source DB:  PubMed          Journal:  Immunol Allergy Clin North Am        ISSN: 0889-8561            Impact factor:   3.479


  8 in total

Review 1.  Pharmacological Management of Hereditary Angioedema with C1-Inhibitor Deficiency in Pediatric Patients.

Authors:  Henriette Farkas
Journal:  Paediatr Drugs       Date:  2018-04       Impact factor: 3.022

Review 2.  Optimum Use of Acute Treatments for Hereditary Angioedema: Evidence-Based Expert Consensus.

Authors:  Hilary Longhurst
Journal:  Front Med (Lausanne)       Date:  2018-03-12

3.  Short-term prophylaxis in patients with angioedema due to C1-inhibitor deficiency undergoing dental procedures: An observational study.

Authors:  Andrea Zanichelli; Mario Ghezzi; Ivan Santicchia; Romualdo Vacchini; Marco Cicardi; Antonella Sparaco; Girolamo Donati; Vito Ranìa; Alberto Busa
Journal:  PLoS One       Date:  2020-03-12       Impact factor: 3.240

4.  Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks.

Authors:  Marc A Riedl; Marcus Maurer; Jonathan A Bernstein; Aleena Banerji; Hilary J Longhurst; H Henry Li; Peng Lu; James Hao; Salomé Juethner; William R Lumry
Journal:  Allergy       Date:  2020-07-06       Impact factor: 13.146

5.  How do patients and physicians communicate about hereditary angioedema in the United States?

Authors:  Gagan Jain; Lauren Walter; Carolyn Reed; Patricia O'Donnell; Jeffrey Troy
Journal:  PLoS One       Date:  2021-12-02       Impact factor: 3.240

Review 6.  Hereditary Angioedema: Diagnostic Algorithm and Current Treatment Concepts.

Authors:  Ankur Kumar Jindal; Anuradha Bishnoi; Sunil Dogra
Journal:  Indian Dermatol Online J       Date:  2021-11-22

Review 7.  Mitigating Disparity in Health-care Resources Between Countries for Management of Hereditary Angioedema.

Authors:  Ankur Kumar Jindal; Avner Reshef; Hilary Longhurst
Journal:  Clin Rev Allergy Immunol       Date:  2021-05-18       Impact factor: 8.667

Review 8.  Recent advances in use of fresh frozen plasma, cryoprecipitate, immunoglobulins, and clotting factors for transfusion support in patients with hematologic disease.

Authors:  Prajeeda M Nair; Matthew J Rendo; Kristin M Reddoch-Cardenas; Jason K Burris; Michael A Meledeo; Andrew P Cap
Journal:  Semin Hematol       Date:  2020-07-27       Impact factor: 3.851

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.